2024 AGM - Chairman's Presentation
Released
Released
Announcement PDF
Annual General Meeting
May 2024
Disclaimer
The following material is for general information purposes only and should not be relied on for the making of any investment decision. Any investment in Elixinol Wellness Limited ACN 621 479 794 (Elixinol Wellness) is subject to
a number of investment risks including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Elixinol Wellness nor any other entity or person in or associated with the Elixinol
Wellness group of companies guarantees any return (whether capital or income) or generally the performance of Elixinol Wellness or the price at which its securities may trade.
In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Elixinol Wellness securities. This presentation is not exhaustive of all of the information a potential investor, or their
professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be,
lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like
Disclosure Document would be required to contain pursuant to the Corporations Act.
This presentation does not take into account any specific objectives, financial situation or needs of investors. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal,
financial and investment advice – those acting without such advice do so at their own risk.
This presentation may contain "forward-looking statements" which are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forwardlooking statements. Any forward-looking statements in this presentation should be considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors that
may lead to actual results differing from any forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof and Elixinol Wellness does
not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. In addition, the
past performance of Elixinol Wellness cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those
outlined in this Presentation.
Neither Elixinol Wellness nor any of its advisers, agents or employees make or give any express or implied representation, warranty or guarantee that the information contained in this presentation or otherwise supplied by or
on behalf of Elixinol Wellness is complete or accurate or that it has been or will be audited or independently verified, or that reasonable care has been or will be taken in compiling, preparing or furnishing the relevant
information. Elixinol does not take any responsibility for any inference, interpretation, opinion or conclusion that any person may draw or form from this presentation.
To the maximum extent permitted at law, Elixinol Wellness and all of its representatives, directors, partners, employees or professional advisers exclude all direct and indirect liability arising out of or in connection with any use
or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), they do not make any representation or give any assurance, guarantee or
warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or
opinion contained in this Presentation or any accompanying, previous or subsequent material or presentation.
This Presentation is current as at 30 May 2024.
Annual General Meeting
2
Chairman’s Address
Annual General Meeting
3
Elixinol Wellness 2023 Overview
TSN Acquisition
The merger with TSN was completed
successfully, and the collaboration
between the businesses is still
generating growth and cost
efficiencies..
Retail Expansion
Mt Elephant expanded its ranging in
Woolworths by 46% to reach a
national audience.
Hemp Foods Gold Oil was ranged
nationally in Woolworths Oil aisle.
Annual General Meeting
Cost Reduction
The substantial cost reductions of
30% have established a solid
foundation for becoming profitable
in FY24 .
New Products
Three New Mt Elephant Baking
Mixes were launched in Q2. FY23
Two new TGA Approved Hemp Seed
Oil CAPS were launched Q3
Sales Growth
Organic sales growth across our
leading brands and hemp ingredients
suggests significant potential for the
overall business.
Culture
A lean, dedicated, and skilled team
has been reconstructed from the
merged businesses, prepared to
tackle fresh challenges and seize new
opportunities.
4
Financial Highlights 2023
• 51% Growth in Australian Revenues: A key market, boosted
by the TSN merger in August 2024 and a 25% increase in B2C
sales of Hemp Foods Australia products.
• 21% Decline in Elixinol Americas eCommerce Revenues:
Reflects a challenging market with an unclear regulatory
pathway.
• 30% Cost Base Reduction: Significant reductions in
operational and corporate expenses, decreasing from $12.2m
in FY22 to $8.6m in FY23.
• 42% Reduction in Normalised Net Operating Cash
Utilisation: Improved from -$11.4m in FY22 to -$6.6m in
FY23, driven by ongoing business optimisation.
• Adjusted EBITDA: Enhanced by revenue growth and cost
reduction initiatives, leading to improved performance.
Annual General Meeting
5
A New Era for Elixinol Wellness
Board of Directors
DAVE FENLON
PAULINE GATELY
NON-EXECUTIVE DIRECTOR
EXECUTIVE DIRECTOR / MARKETING
• Over 30 years’ experience in FMCG and
Consumer Goods sectors.
• Former CEO roles at BWX Limited and The
Platform Alliance Group.
• Strategic planning and business
transformation expertise from roles with
Tesco and Safeway.
• Extensive Board experience in FMCG, mining,
financial technology, and non-profit sectors.
• Proven success in strategy, risk management,
and business transformation, including
leading companies through IPOs and mergers.
• 20+ years in investment banking, specializing
in investment strategy, research, and funds
management.
• Over a decade of strategic leadership with a
track record of driving growth and innovation.
• Successfully led Tom Organic as General
Manager and spearheaded global initiatives
with L'Oréal.
• Proven ability to drive results in dynamic
environments
INDEPENDENT CHAIR AND NON-EXECUTIVE DIRECTOR
Annual General Meeting
NATALIE BUTLER
6
A New Era for Elixinol Wellness
As we forge ahead in a new era for Elixinol Wellness, we are focused
on building a profitable business around our house of brands tailored
to the future needs of consumers.
What Sets Us Apart:
• Emphasis on natural, nutrient-rich, and clean-label products.
• Alignment with global consumer trends towards preventive health and aging well.
• Market positioning as the leader in hemp-based nutrition & wellness
Annual General Meeting
7
A New Era for Elixinol Wellness
HEMP FOODS AUSTRALIA
MT. ELEPHANT
ELIXINOL USA
FIELD DAY
Plant-based nutrition and
wellness products
Wholefood baking mixes
for healthy indulgence
CBD-focused
Nutraceuticals
Wholefood Pet
Supplements
Annual General Meeting
8
A New Era for Elixinol Wellness
Healthy plant-based products for everyone, every day
Human Nutrition
Hemp Foods
Mt Elephant
Soul Seeds
Annual General Meeting
Shared Synergies driving a revolution in plant-based
health and wellness products & ingredients
Pet Nutrition
Nutraceuticals
Field Day
Ananda Equine
Elixinol USA
Hemp Foods
Ingredients:
Hemp
Australian Primary Hemp
Hemp Foods
Ananda Foods
Ingredients:
Native Superfoods
The Australian
Superfoods Company
9
Q1 FY24 Key Highlights
Adjusted EBITDA improvement and 6th Qtr. of revenue growth
• Compelling Q1 FY24 performance. 6th consecutive quarter of revenue
growth. Group revenue up 76% to $3.0M from $1.7M a year ago.
• Expanded brand portfolio delivering impressive results. Australian
revenue jumped 140% to a record $2.5m.
• Completion of Ananda Food acquisition. Acquisition cements EXL’s
leadership in the Australian hemp market, improves unit economics, and
adds complementary products
• Americas: Positive contribution to Group EBITDA.
• Continued focus on costs. Leaner cost structure. Net operating cash flows of
$0.2M (ex one-offs) down from $1.5M a year ago.
• Divestment of minority stake in Pet Releaf. $ 2.3M sale proceeds
• On course to reach EBITDA breakeven from mid-2024. Reconfirming sales
guidance of $16M- $20M for the full year.
Annual General Meeting
10
Harnessing the Power of Hemp
Acquisition of Ananda Food confirms Elixinol Wellness as the undisputed leader in the Australian Hemp
Market, leveraging hemp’s immense potential as a "future food" and a sustainable crop.
MARKET DOMINANCE
Annual General Meeting
RETAIL DISTRIBUTION
11
Brand
Highlights
12
Mt. Elephant Highlights
• Expanded Ranging in Woolworth in Q2 FY23
• Expanded national distribution into Coles in 2024
• Strong growth of base by 25% q-o-q
• Tracking above category average in both loyalty and eComm
• Three new products launched in Q2 FY23
Mt Elephant Sales
Annual General Meeting
13
Hemp Foods Highlights
• Gold Oil expanded Woolworths ranging in Jan 2023
• Sales progress driven by organic growth in protein business
• Launched TGA Omega Oil Caps in Q3 FY23
HFA Sales
Annual General Meeting
Gold Protein Sales
14
Elixinol USA Highlights
• FY23: $2.64 million revenue despite regulatory challenges.
• Stable eCommerce Revenue: Servicing and subscription orders contributed one-third of eCommerce revenue.
• Lean Operations: Poised for positive FY24 EBITDA contribution
Elixinol Sales
Annual General Meeting
15
Positioned for Strong Future Growth
Market Leadership
• With two significant mergers and acquisitions finalised,
Elixinol has become the unparalleled leader in
Australia's hemp industry.
• Capitalise on our position as pioneer and early leader in
plant-based native superfoods
Sustained Expansion
• Emphasise product innovation for better profitability
and market acceptance
• Expand aggressively in retail and form partnerships,
particularly in pharmacy and pet nutrition
• Explore new hemp opportunities in beauty, building,
equine, and pet sectors using a whole plant approach
Annual General Meeting
Operational Efficiency
• Sales and operational synergies propel the path towards
profitability and a sustainable business model.
• A lean, agile, and experienced team is committed to
continuous growth and efficiency.
True Differentiation
• Aligned with global trends in preventive health to
develop and promote health products tailored for
target consumers.
16
Thank you!
Share your feedback
Discover